JW Pharmaceutical said on the 12th that it posted standalone sales of 198.5 billion won in the first quarter. That was up 8% from a year earlier. Operating profit was 31.7 billion won, and net profit was 28.5 billion won. Those rose 40% and 62%, respectively, from the same period a year earlier.
By institutional sector, prescription drugs generated 164.9 billion won in sales, and over-the-counter drugs generated 15.0 billion won. Among prescription drugs, infusion sales were 62.8 billion won. High value-added nutrition infusions drove the improvement in results.
The hyperlipidemia treatment Livalozet recorded 28.3 billion won, and the hemophilia treatment Hemlibra recorded 23.1 billion won in sales. Those were up 21% and 60%, respectively, from a year earlier. Friends, a brand that manages the eyes such as artificial tears, and the wound-care band Haimom also posted stable results.
A JW Pharmaceutical official said, "We will expand investment in research and development (R&D) to secure future growth drivers."